Adcetris as Consolidation Therapy After Stem Cell Transplant in HL

Seattle Genetics, along with partner Takeda Pharmaceutical Company Ltd., is announcing positive top-line data from the randomized phase III AETHERA study on Adcetris as consolidation therapy following an autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma.

Consolidation therapy targets cancer cells that may remain after initial treatment.

The phase III AETHERA study compared single-agent Adcetris to placebo in 329 Hodgkin lymphoma patients at high risk of relapse. The primary 'endpoint' (something that can be objectively measured) of the study was progression-free survival (PFS).

According to the results, compared to placebo patients given Adcetris in the consolidation setting had a 75 percent improvement in PFS. Seattle Genetics administered Adcetris to those patients in the placebo arm of the study when their disease showed progression.

The company will consider this trial from the endpoint of overall survival in 2016, but before then they will present detailed versions of this data at the annual meeting of the American Society of Hematology (ASH) in December 2014. They will likely submit a supplemental biologics license application (BLA) to the FDA for Adcetris for this indication in 2015.

Adcetris is also being evaluated in three other phase III studies: ALCANZA (relapsed cutaneous T-cell lymphoma (CTCL); ECHELON-1 (front-line advanced classical Hodgkin lymphoma) and ECHELON-2 (front-line CD30-positive MTCL, including systemic anaplastic large cell lymphoma (sALCL).

Source: Zacks

lymphoma roundup

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...